Cystic fibrosis precision therapeutics: Emerging considerations
Sign Up to like & getrecommendations! Published in 2019 at "Pediatric Pulmonology"
DOI: 10.1002/ppul.24547
Abstract: Small molecules that address fundamental defects underlying cystic fibrosis (CF), including modulators such as the approved drugs ivacaftor, lumacaftor, tezacaftor, and elexacaftor, have advanced dramatically over the past few years and are transforming care and… read more here.
Keywords: cystic fibrosis; fibrosis; therapeutics emerging; precision therapeutics ... See more keywords
Abstract CN05-03: Precision therapeutics with DNA-damaging agents
Sign Up to like & getrecommendations! Published in 2018 at "Molecular Cancer Therapeutics"
DOI: 10.1158/1535-7163.targ-17-cn05-03
Abstract: Precision therapeutics can be defined as the ability to prescribe effective (curative) therapies only to those patients who will respond, while limiting toxicity to normal tissues and minimizing side effects. The paradigm for precision therapeutics… read more here.
Keywords: medicine; dna damaging; response; precision therapeutics ... See more keywords
Advances toward precision therapeutics for developmental and epileptic encephalopathies
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Neuroscience"
DOI: 10.3389/fnins.2023.1140679
Abstract: Developmental and epileptic encephalopathies are childhood syndromes of severe epilepsy associated with cognitive and behavioral disorders. Of note, epileptic seizures represent only a part, although substantial, of the clinical spectrum. Whether the epileptiform activity per… read more here.
Keywords: toward precision; precision therapeutics; developmental epileptic; epileptic encephalopathies ... See more keywords